Of chimeric antigen receptors and antibodies: OX40 and 41BB costimulation sharpen up T cell-based immunotherapy of cancer

Immunotherapy. 2013 Jul;5(7):677-81. doi: 10.2217/imt.13.54.

Authors

Andreas A Hombach¹, Hinrich Abken

Affiliation

¹ Center for Molecular Medicine Cologne-CMMC, University of Cologne, and Department I Internal Medicine, University Hospital Cologne, Uniklinik Köln, Robert-Koch-Straße 21, D-50931 Köln, Cologne, Germany.

PMID: 23829616
DOI: 10.2217/imt.13.54

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Animals
Antigens, Differentiation / immunology*
Clinical Trials as Topic
Humans
Immunotherapy, Adoptive / methods*
Immunotherapy, Adoptive / trends
Lymphocyte Activation
Neoplasms / immunology
Neoplasms / therapy*
Receptor Cross-Talk
Receptors, Antigen, T-Cell / genetics
Receptors, Antigen, T-Cell / metabolism*
Recombinant Fusion Proteins / genetics
T-Lymphocytes / immunology
T-Lymphocytes / metabolism*
Tumor Necrosis Factor Receptor Superfamily, Member 9 / genetics
Tumor Necrosis Factor Receptor Superfamily, Member 9 / immunology*

Substances

Antigens, Differentiation
OX40Ig
Receptors, Antigen, T-Cell
Recombinant Fusion Proteins
Tumor Necrosis Factor Receptor Superfamily, Member 9